Biotechnology

Filter

Current filters:

None

Popular Filters

40 to 64 of 2406 results

Janssen’s Olysio/sofosbuvir combination cleared by FDA

Janssen’s Olysio/sofosbuvir combination cleared by FDA

06-11-2014

The Food and Drug Administration has approved US health care giant Johnson & Johnson's Olysio (simeprevir)…

Anti-viralsBiotechnologyJohnson & JohnsonMedivirOlysioRegulationsofosbuvirUSA

Genmab reports nine month interim results, including $31 million revenue increase on 2013

Genmab reports nine month interim results, including $31 million revenue increase on 2013

06-11-2014

Danish biotech company Genmab has reported its nine-month interim results, including an increase in revenue…

BiotechnologydaratumumabDenmarkDuoBodyFinancialGenmabOfatumumab Injection

Vertex seeks regulatory approval for lumacaftor/ivacaftor combination for CF

05-11-2014

US biotech firm Vertex Pharmaceuticals has filed for marketing approval for a fully co-formulated combination…

BiotechnologyEuropeivacaftorlumacaftorRare diseasesRegulationUSAVertex Pharmaceuticals

Non-small cell lung cancer pipeline shows shift away from traditional chemotherapies, says GBI Research

Non-small cell lung cancer pipeline shows shift away from traditional chemotherapies, says GBI Research

05-11-2014

There is cause for optimism in the non-small cell lung cancer (NSCLC) treatment pipeline, according to…

BiotechnologyGBI ResearchHealth Medical PharmaOncologyResearch

Regeneron third-qtr net profit plunges despite strong sales growth

Regeneron third-qtr net profit plunges despite strong sales growth

04-11-2014

US biotech firm Regeneron posted revenue of $725.8 million for the third quarter of 2014, a rise of 22%…

alirocumabBayerBiotechnologydupilumabEyleaFinancialOphthalmicsRegeneronResearchSanofisarilumab

Amgen’s trebananib disappoints in ovarian cancer trial

Amgen’s trebananib disappoints in ovarian cancer trial

04-11-2014

USA-based Amgen, the world’s largest independent biotech firm, revealed that a late-stage trial of…

AmgenBiotechnologyOncologyResearchtrebananib

Pharming strengthens balance sheet with $20 million milestone from Salix

Pharming strengthens balance sheet with $20 million milestone from Salix

04-11-2014

Dutch biotech company Pharming Group says it has received a $20 million milestone payment from the USA’s…

BiotechnologyFinancialPharming GroupRare diseasesRuconestSalix Pharmaceuticals

AstraZeneca, Pharmacyclics and Janssen team up on Imbruvica and MEDI4736 combination trial

AstraZeneca, Pharmacyclics and Janssen team up on Imbruvica and MEDI4736 combination trial

04-11-2014

Anglo-Swedish drug major AstraZeneca and US health care giant Johnson & Johnson’s Europe-based subsidiary…

AstraZenecaBiotechnologyImbruvicaJanssenMEDI4736OncologyPharmacyclicsResearchUK

Bristol-Myers enters option agreement to acquire Danish firm

Bristol-Myers enters option agreement to acquire Danish firm

03-11-2014

US pharma major Bristol-Myers Squibb has entered into an exclusive option agreement to buy Denmark-based…

BiotechnologyBristol-Myers SquibbGalecto BiotechMergers & AcquisitionsRespiratory and PulmonaryTD139

Nymox plunges as NX1207 fails Ph III endpoints

03-11-2014

Canada-based biotech firm Nymox Pharmaceutical saw its shares decimated in pre-market trading after it…

BiotechnologyMen's HealthNX1207Nymox PharmaRecordatiResearch

Celladon links with Lonza for commercial manufacturing of Mydicar

03-11-2014

Swiss chemical supplier Lonza and US biotech firm Celladon Corp have entered into an agreement providing…

BiotechnologyCardio-vascularCelladonFinancialLonzaProduction

BioOutsource preparing for biosimilars boom

03-11-2014

Scotland, UK-based vaccine and microbiological testing company BioOutsource today announced a major initiative…

Anti-Arthritics/RheumaticsBioOutsourceBiosimilarsBiotechnologyResearchRespiratory and Pulmonary

Biogen Idec and SOBI’s Elocta MAA validated in Europe

01-11-2014

Biotechnology companies Biogen Idec of the USA and Swedish Orphan Biovitrum said on Friday that the European…

Biogen IdecBiotechnologyEloctaEloctateEuropeHematologyRegulationSwedish Orphan Biovitrum

Actinogen acquires Edinburgh BioQuarter spin-out Corticrine

Actinogen acquires Edinburgh BioQuarter spin-out Corticrine

31-10-2014

Australian biotech firm Actinogen has acquired Edinburgh BioQuarter spin-out, Corticrine.

ActinogenBiotechnologyCorticrineEdinburgh BioQuarterMergers & AcquisitionsNeurological

Specialised Therapeutics' Abraxane to be reimbursed via Australian PBS

Specialised Therapeutics' Abraxane to be reimbursed via Australian PBS

31-10-2014

Australian biopharma company Specialised Therapeutics is to have its Abraxane (nanoparticle albumin-bound…

AbraxaneAustraliaBiotechnologyOncologyRegulationSpecialised Therapeutics Australia

Department of Defense contracts Profectus to develop its VesiculoVax Zaire-Ebola virus vaccine

Department of Defense contracts Profectus to develop its VesiculoVax Zaire-Ebola virus vaccine

31-10-2014

The US Department of Defense has contracted the manufacture and IND-enabling preclinical testing of the…

Anti-viralsBiotechnologyProfectus BioSciencesResearchUSAVesiculoVax Zaire-Ebola

Affinivax launches, aiming to develop novel conjugate vaccine

30-10-2014

Affinivax, a US biotechnology company dedicated to developing novel vaccines, today announced its launch…

AffinivaxBiotechnologyFinancialResearchVaccines

EMA guidance on facilitating global development of biosimilars

EMA guidance on facilitating global development of biosimilars

30-10-2014

The European Medicines Agency has published its revised overarching guideline on biosimilars, or follow-on…

BiosimilarsBiotechnologyEuropeRegulation

SOBI increases revenues by 25%, boosted by a doubling of Orfadin sales

SOBI increases revenues by 25%, boosted by a doubling of Orfadin sales

30-10-2014

Biotech firm Swedish Orphan Biovitrum has announced total revenues of 665.9 million Swedish kronor ($99.8…

BiotechnologyBusiness FinanceOrfadinSobiSweden

Xencor regains rights to XmAb5871 from Amgen

29-10-2014

US drug developer Xencor revealed yesterday that it has regained all development and commercial rights…

AmgenAnti-Arthritics/RheumaticsBiotechnologyImmunologicalsLicensingResearchXencorXmAb5871

Synthetic Genomics appoints Oliver Fetzer as chief executive

Synthetic Genomics appoints Oliver Fetzer as chief executive

29-10-2014

Synthetic biology company Synthetic Genomics has appointed Oliver Fetzer as the company’s new chief…

BiotechnologyBoardroomSGISynthetic GenomicsUSA

40 to 64 of 2406 results

Parexel

Parexel

Back to top